CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 8-K

What Happened

• Charles River Laboratories (CRL) announced on February 18, 2026 (Form 8-K) that it appointed Glenn Coleman, age 58, as Corporate Executive Vice President and Chief Financial Officer with a tentative start date of April 6, 2026. Mr. Coleman succeeds Michael G. Knell, who has been serving as interim CFO since September 2025 and will return to his role as Corporate Senior Vice President and Chief Accounting Officer.
• Mr. Coleman brings more than 30 years of financial and operational experience, including recent roles as CFO & Chief Administrative Officer of Premier, Inc. (since 2024), CFO of DENTSPLY SIRONA (2022–2024), and senior leadership at Integra Life Sciences (2014–2022).

Key Details

• Base salary: $800,000 per year (employment is at-will).
• 2026 bonus: Eligible for Executive Incentive Compensation Program with a target equal to 85% of base salary for 2026, prorated to hire date.
• 2026 equity: Annual equity award in May 2026 valued at $3,000,000 (60% Performance Share Units, 40% Restricted Stock Units).
• One-time new hire compensation: $1,875,000 cash ( $1,000,000 after 6 months; $875,000 after 12 months) and a $3,500,000 one-time RSU award vesting 25% per year over four years.
• The Offer Letter is attached as Exhibit 10.1 to the 8-K. The company disclosed no family relationships or transactions requiring Item 404(a) disclosure.

Why It Matters

• Leadership change at the CFO level is material for investors because the CFO oversees financial reporting, capital allocation, and investor communications. Mr. Coleman’s extensive healthcare and operations experience could influence CRL’s financial strategy and execution.
• The compensation structure (significant cash, equity, and PSU components) aligns the new CFO’s pay with multi-year performance and retention, which can affect future dilution and executive expense trends visible in CRL’s filings.